menu
    • menu

    Company profile for Asceneuron

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Asceneuron is a clinical stage biotech company dedicated to targeting the root causes of neurodegenerative diseases such as the intracellular aggregation of the microtubule-associated protein tau. The pipeline reflects our ambition to develop treatments for a wide a range of neurodegenerative diseases including orphan tauopathies, Alzheimer’s and Parkinson’s disease. Asceneuron has two clinical stage small molecule O-GlcNA...
    Asceneuron is a clinical stage biotech company dedicated to targeting the root causes of neurodegenerative diseases such as the intracellular aggregation of the microtubule-associated protein tau. The pipeline reflects our ambition to develop treatments for a wide a range of neurodegenerative diseases including orphan tauopathies, Alzheimer’s and Parkinson’s disease. Asceneuron has two clinical stage small molecule O-GlcNAcase inhibitors in development for the treatment of proteinopathies including Parkinson’s Disease, Alzheimer’s disease and related disorders.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    AsceneuronSwitzerland Flag
    Country
    Country
    Switzerland
    Address
    Address
    EPFL Innovation Park Bâtiment B CH-1015 Lausanne
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.asceneuron.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/asceneuron-sa/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/asceneuron_sa

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Novo owner backs Swiss biotech Asceneuron in $100 million round
    Novo owner backs Swiss biotech Asceneuron in $100 million round

    17 Jul 2024

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/novo-owner-backs-swiss-biotech-asceneuron-100-million-round-2024-07-16/

    REUTERS
    17 Jul 2024
    Share Share
    EQT Life Sciences Invests In Asceneuron's Series C Financing Round
    EQT Life Sciences Invests In Asceneuron's Series C Financing Round

    15 Jul 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/eqt-life-sciences-invests-in-asceneuron-a-neurodegeneration-therapeutics-company-as-part-of-usd-100-million-series-c-financing-round-302197836.html

    PR NEWSWIRE
    15 Jul 2024
    Share Share
    Asceneuron Secures $100M For Neurodegenerative Disease Therapeutics
    Asceneuron Secures $100M For Neurodegenerative Disease Therapeutics

    15 Jul 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/asceneuron-secures-100-million-series-c-financing-to-advance-groundbreaking-therapeutics-in-neurodegenerative-diseases-302197035.html

    PR NEWSWIRE
    15 Jul 2024
    Share Share
    Asceneuron Joins Critical Path for Alzheimer's Disease Consortium
    Asceneuron Joins Critical Path for Alzheimer's Disease Consortium

    26 Mar 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/asceneuron-joins-critical-path-for-alzheimers-disease-consortium-302098497.html

    PR NEWSWIRE
    26 Mar 2024
    Share Share
    Asceneuron Expands Scientific Advisory Board
    Asceneuron Expands Scientific Advisory Board

    06 Mar 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/asceneuron-expands-scientific-advisory-board-with-world-leading-experts-in-neurodegenerative-diseases-302080344.html

    PR NEWSWIRE
    06 Mar 2024
    Share Share
    Industry Veteran Abbas Hussain Appointed as Chair of Asceneuron
    Industry Veteran Abbas Hussain Appointed as Chair of Asceneuron

    18 Dec 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/industry-veteran-abbas-hussain-appointed-as-chair-of-asceneuron-302016860.html

    PR NEWSWIRE
    18 Dec 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search